Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formal UK Medical Devices Legislation Expected In Spring

Executive Summary

The Queen’s speech last month signaled new legislation for medical devices after the UK leaves the umbrella of EU legislation, following the December election result. The bill is expected to enter its second reading in March 2020.

You may also be interested in...



New Report Calls For UK NHS To Provide Early Access To Medtech

A new report from the UK's Medical Technology Group calls for NHS England to establish an Early Access to Medical Technology scheme like the one in place for drugs. The UK coalition of medical device manufacturers, patient groups and research charities aims to improve access to new medical technologies in the NHS.

UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.

Queen’s Speech Promises More NHS Spending After Brexit

The new UK government’s political priorities for the years ahead were laid out in the 19 December Queen’s speech, which inevitably centred around the UK’s departure from the EU next month and the negotiation of a free trade deal with the EU. A rise in NHS spending was promised, and new legislation on the future of medicines regulation is on the horizon.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel